| SPI1 | |
|---|---|
| Full Name | PU.1 Transcription Factor / Spi-1 Proto-Oncogene |
| Gene Symbol | SPI1 (PU.1) |
| Chromosomal Location | 19q13.3 |
| NCBI Gene ID | 6678 |
| OMIM | 165010 |
| Ensembl ID | ENSG00000135336 |
| UniProt ID | P17947 |
| Protein Length | 270 amino acids |
| Category | Transcription Factor / Master Regulator |
| Associated Diseases | Alzheimer's Disease, [Parkinson's Disease](/diseases/parkinsons-disease), Multiple Sclerosis, AML |
SPI1 (also known as PU.1 or Spi-1) encodes a transcription factor of the E26 transformation-specific (ETS) family. PU.1 is a master regulator of microglial development and function, and genome-wide association studies (GWAS) have identified SPI1 as a significant Alzheimer's disease risk gene [1]. The protein controls the expression of numerous genes critical for microglial identity, homeostasis, and immune responses, making it a central player in neuroinflammation and neurodegenerative disease pathogenesis [2].
What makes SPI1 particularly important in the AD context is its role as a master transcriptional regulator of the microglial genome. PU.1 controls the expression of multiple other AD risk genes including TREM2, CD33, CSF1R, and PLCG2, positioning it at the top of a hierarchy of microglial risk genes [3].
The PU.1 protein (270 amino acids) contains several well-defined functional domains:
| Domain | Location | Function |
|---|---|---|
| ETS DNA-binding domain | C-terminal (aa 170-270) | Binds ETS motifs (GGAA/T) in DNA |
| PEST domain | N-terminal (aa 1-100) | Proline, glutamic acid, serine, threonine-rich |
| Transactivation domain | Central (aa 100-170) | Recruits co-activators |
| Inhibitory domain | Mid (aa 150-170) | Auto-inhibition, phosphorylation target |
ETS DNA-binding domain: The conserved ETS domain contains a winged helix-turn-helix motif that recognizes the core DNA sequence "GGAA/T". This domain mediates binding to enhancer and promoter elements of target genes.
PEST region: The N-terminal proline-rich region lacks defined structure but serves as a docking site for protein-protein interactions with transcriptional co-activators and chromatin remodelers.
Auto-inhibitory module: An internal inhibitory region keeps PU.1 in a low-activity state under basal conditions. Phosphorylation or binding partners can release this inhibition.
PU.1 functions as a master regulator of the myeloid cell lineage, including microglia:
PU.1 → TREM2, CD33, CSF1R, PLCG2, APOE, ...
↓
Microglial Development & Function
↓
AD Risk Modification
PU.1 directly regulates genes critical for microglial function:
| Gene | Function | PU.1 Relationship |
|---|---|---|
| TREM2 | Phagocytosis receptor | Direct transcriptional target |
| CD33 | Phagocytosis inhibition | Direct transcriptional target |
| CSF1R | Growth factor receptor | Direct transcriptional target |
| PLCG2 | Signaling enzyme | Direct transcriptional target |
| CX3CR1 | Chemokine receptor | Direct transcriptional target |
| AIF1/IBA1 | Microglial marker | Direct transcriptional target |
PU.1 exerts its effects through multiple molecular mechanisms [4]:
PU.1 is essential for microglial development throughout the lifespan:
PU.1 influences the transition between microglial activation states:
| State | PU.1 Activity | Markers |
|---|---|---|
| Homeostatic | Baseline expression | P2RY12, TMEM119 |
| DAM (Disease-Associated) | Increased | TREM2, APOE, LPL |
| MGnD (Neurodegenerative) | Altered | TREM2, CD11b |
| Activated | Increased | CD68, IBA1 |
One of the most critical PU.1 targets is TREM2, a major AD risk gene:
PU.1 controls genes essential for microglial phagocytosis [6]:
SPI1 was identified as an AD risk gene through large-scale GWAS meta-analyses:
| Study | Key Finding | Effect |
|---|---|---|
| Sims et al. 2017 | Rare variant analysis | Implicated microglial pathway |
| Huang et al. 2017 | Expression QTL | Lower PU.1 = delayed onset |
| Jansen et al. 2019 | GWAS meta-analysis | Confirmed association |
| Kunkle et al. 2019 | Genetic meta-analysis | Confirmed association |
Huang et al. (2017) discovered a common SPI1 haplotype that lowers PU.1 expression and delays AD onset:
SPI1 risk alleles are associated with:
SPI1 variants influence AD through multiple mechanisms:
PU.1 is a well-known oncogene in AML:
PU.1 interacts with multiple proteins relevant to neurodegeneration:
| Interactor | Function | AD Relevance |
|---|---|---|
| IRF4 | Transcription factor | Co-regulation of microglial genes |
| IRF8 | Transcription factor | Myeloid cell development |
| GATA2 | Transcription factor | Hematopoietic development |
| C/EBPα | Transcription factor | Myeloid differentiation |
| TREM2 | Phagocytosis receptor | PU.1 target gene |
| CD33 | Phagocytosis inhibition | PU.1 target gene |
| CSF1R | Growth factor receptor | PU.1 target gene |
SPI1 shows highest expression in:
| Cell Type | Expression Level | Notes |
|---|---|---|
| Microglia | Very High | Primary CNS expression |
| Perivascular macrophages | High | Border-associated |
| Monocytes | High | Peripheral immune |
| Neurons | Very Low | Minimal |
| Astrocytes | Very Low | Minimal |
| Cell Type | Expression Level |
|---|---|
| Myeloid progenitors | Highest |
| Monocytes/Macrophages | High |
| B cells | High |
| T cells | Low |
| NK cells | Very low |
Given its central role in microglial function, PU.1 represents a promising but challenging therapeutic target:
| Strategy | Approach | Status |
|---|---|---|
| Gene expression modulation | Reduce PU.1 expression | Theoretical |
| Downstream targeting | Modulate PU.1 targets | Research |
| Epigenetic modulators | HDAC inhibitors | Research |
| Microglial replacement | Replace dysfunctional cells | Preclinical |
PU.1 is a master regulator with complex effects:
More tractable therapeutic strategies include:
| Gene | Primary Function | SPI1 Relationship |
|---|---|---|
| TREM2 | Phagocytosis activation | PU.1 direct target |
| CD33 | Phagocytosis inhibition | PU.1 direct target |
| PLCG2 | Signaling | PU.1 direct target |
| CSF1R | Growth factor | PU.1 direct target |
| SPI1 | Master regulator | Primary |
PU.1 serves as the cornerstone of the microglial transcriptional identity network. Unlike most tissue-resident macrophages in the body, microglia originate from a distinct embryonic progenitor population in the yolk sac that populates the brain during early development [8]. This unique developmental origin is reflected in their specialized transcriptional program, with PU.1 at its apex.
The microglial identity network controlled by PU.1 includes:
This network ensures that microglia maintain their unique identity throughout life while remaining responsive to pathological changes in the brain.
The transition from homeostatic microglia to disease-associated microglia (DAM) represents a critical pathological response in AD. PU.1 plays a central role in this transition:
Stage 1 DAM (TREM2-independent):
Stage 2 DAM (TREM2-dependent):
The PU.1-TREM2 Axis:
PU.1 influences chromatin architecture to enable microglial gene expression:
This epigenetic role explains how SPI1 variants can have lasting effects on microglial function without changing protein sequence.
Microglial aging is a key factor in AD pathogenesis:
Several mouse models have been developed to study SPI1 function:
| Model | Approach | Phenotype |
|---|---|---|
| Spi1 KO | Complete knockout | Embryonic lethal, no microglia |
| Spi1 flox | Conditional knockout | Microglial deficiency |
| Spi1 OE | Overexpression | Increased inflammation |
| Humanized | Human SPI1 knock-in | Species-specific function |
Mouse models have revealed:
SPI1 expression could serve as a biomarker:
Targeting PU.1 or its network has therapeutic potential:
Several factors complicate PU.1-targeted therapy:
SPI1/PU.1 is a master transcription factor that controls microglial development, identity, and function. As an AD risk gene, it sits atop a hierarchy of microglial genes including TREM2, CD33, CSF1R, and PLCG2. The discovery of a protective SPI1 haplotype that lowers PU.1 expression suggests that modulating microglial activation could be therapeutic. However, directly targeting PU.1 is challenging due to its essential and pleiotropic functions. Alternative strategies targeting downstream genes or the broader microglial activation program may be more tractable. Understanding PU.1's role in AD continues to provide insights into microglial biology and therapeutic targeting.
Sims R, et al. Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in AD. Nat Genet. 2017. ↩︎
Hansen DV, et al. Microglia in Alzheimer's disease. Nat Rev Neurosci. 2018. ↩︎
Zhou Y, et al. Divergent and convergent roles of microglia in AD. Nat Rev Neurosci. 2020. ↩︎
Schwartz K, et al. PU.1 controls transcription factor networks in microglia. Nat Neurosci. 2020. ↩︎
Yang J, et al. PU.1 is required for microglial development. Development. 2019. ↩︎
Wang Y, et al. TREM2 mediates microglial phagocytosis of amyloid plaques. Nat Neurosci. 2019. ↩︎
Rosenthal SL, et al. A microglia-related impact on AD. Mol Psychiatry. 2018. ↩︎
Gomez-Nicola D, et al. Microglial dynamics in AD progression. Nat Rev Neurol. 2019. ↩︎